Discontinuation of antiresorptive therapies: A comparison between 1998-2001 and 2002-2004 among osteoporotic women

被引:29
作者
Blouin, Julie
Dragomir, Alice
Ste-Marie, Louis-Georges
Fernandes, Julio Cesar
Perreault, Sylvie
机构
[1] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
[2] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1210/jc.2006-1856
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Studies having reported high rates of discontinuation of antiresorptive therapies (ART) may not reflect their actual use. Objectives: We compared probability of discontinuation among women aged 70 yr or older with a diagnosis of osteoporosis or recent osteoporotic fracture having started ART (alendronate, risedronate, cyclical etidronate, raloxifene, nasal calcitonin) between 1998-2001 or 2002-2004. Patients and Methods: We constructed two cohorts of women using Regie de l'Assurance Maladie du Quebec databases. Discontinuation was defined as a lapse of 30 d or longer after completion of a refill. Switching from one ART to another was allowed. Probability of discontinuation was estimated using Kaplan-Meier analysis. Multivariate Cox models were used to identify potential determinants of ART discontinuation over 1 yr. Results: After 1 yr, probability of discontinuation was slightly lower in the 2002-2004 cohort than the 1998-2001 cohort (52.2 vs. 57.5%; P < 0.001). This difference remained significant after adjusting for determinants [adjusted rate ratio (RR) 0.92, 95% confidence interval (CI) 0.87-0.98]. Significant determinants of ART discontinuation within 1 yr included bone mineral density testing (RR 0.77; CI 0.73-0.82) performed within 2 yr prior to initiation of therapy and having consulted more than two pharmacies (RR 1.15; CI 1.06-1.25) in the year before starting therapy. In the 2002-2004 cohort, when switching was allowed, women initiating a once-weekly regimen of alendronate or risedronate did not show a 1-yr risk of discontinuation different from women initiating daily regimens of the same drugs (RR 0.90; CI 0.82-1.00). Conclusions: Even if new dosing regimens were introduced, discontinuation of ART among osteoporotic women remains high.
引用
收藏
页码:887 / 894
页数:8
相关论文
共 34 条
  • [31] Effect of the women's health initiative on osteoporosis therapy and expenditure in Medicaid
    Udell, JA
    Fischer, MA
    Brookhart, MA
    Solomon, DH
    Choudhry, NK
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (05) : 765 - 771
  • [32] RECALL ACCURACY FOR PRESCRIPTION MEDICATIONS - SELF-REPORT COMPARED WITH DATABASE INFORMATION
    WEST, SL
    SAVITZ, DA
    KOCH, G
    STROM, BL
    GUESS, HA
    HARTZEMA, A
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 142 (10) : 1103 - 1112
  • [33] Validation of diagnostic codes within medical services claims
    Wilchesky, M
    Tamblyn, RM
    Huang, A
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (02) : 131 - 141
  • [34] Compliance with pharmacologic therapy for osteoporosis
    Yood, RA
    Emani, S
    Reed, JI
    Lewis, BE
    Charpentier, M
    Lydick, E
    [J]. OSTEOPOROSIS INTERNATIONAL, 2003, 14 (12) : 965 - 968